Bonnie M Scott1, Robert S Eisinger2, Matthew R Burns2, Janine Lopes2, Michael S Okun2, Aysegul Gunduz2, Dawn Bowers2. 1. From the Department of Clinical and Health Psychology (B.M.S., D.B.), Departments of Neuroscience (R.S.E., A.G.) and Neurology (M.R.B., J.L., M.S.O.), Norman Fixel Institute of Neurological Diseases, and J. Crayton Pruitt Department of Biomedical Engineering (A.G.), University of Florida, Gainesville. bonnie.m.scott@phhp.ufl.edu. 2. From the Department of Clinical and Health Psychology (B.M.S., D.B.), Departments of Neuroscience (R.S.E., A.G.) and Neurology (M.R.B., J.L., M.S.O.), Norman Fixel Institute of Neurological Diseases, and J. Crayton Pruitt Department of Biomedical Engineering (A.G.), University of Florida, Gainesville.
Abstract
OBJECTIVE: To empirically test whether apathy and impulse control disorders (ICDs) represent independent, opposite ends of a motivational spectrum. METHODS: In this single-center, cross-sectional study, we obtained retrospective demographics and clinical data for 887 patients with idiopathic Parkinson disease (PD) seen at a tertiary care center. Mood and motivation disturbances were classified using recommended cutoff scores from self-reported measures of apathy, ICD, anxiety, and depression. RESULTS: Prevalence rates included 29.0% of patients with PD with depression, 40.7% with anxiety, 41.3% with apathy, 27.6% with ICDs, and 17.0% with both apathy and ICD. The majority (61.6%) of people reporting clinically significant ICDs also reported clinically significant apathy, and more than a third of patients with apathy (41.3%) also reported elevated ICD. Anxiety and depression were highest in patients with both apathy and ≥1 ICDs. Dopamine agonist use was higher in people with only ICD compared to people with only apathy. Mood significantly interacted with demographic variables to predict motivational disturbances. CONCLUSIONS: Motivational disturbances are common comorbid conditions in patients with PD. In addition, these complex behavioral syndromes interact with mood in clinically important ways that may influence the design of future clinical trials and the development of novel therapies. This study challenges the concept of apathy and ICD in PD as opposite ends of a spectrum.
OBJECTIVE: To empirically test whether apathy and impulse control disorders (ICDs) represent independent, opposite ends of a motivational spectrum. METHODS: In this single-center, cross-sectional study, we obtained retrospective demographics and clinical data for 887 patients with idiopathic Parkinson disease (PD) seen at a tertiary care center. Mood and motivation disturbances were classified using recommended cutoff scores from self-reported measures of apathy, ICD, anxiety, and depression. RESULTS: Prevalence rates included 29.0% of patients with PD with depression, 40.7% with anxiety, 41.3% with apathy, 27.6% with ICDs, and 17.0% with both apathy and ICD. The majority (61.6%) of people reporting clinically significant ICDs also reported clinically significant apathy, and more than a third of patients with apathy (41.3%) also reported elevated ICD. Anxiety and depression were highest in patients with both apathy and ≥1 ICDs. Dopamine agonist use was higher in people with only ICD compared to people with only apathy. Mood significantly interacted with demographic variables to predict motivational disturbances. CONCLUSIONS: Motivational disturbances are common comorbid conditions in patients with PD. In addition, these complex behavioral syndromes interact with mood in clinically important ways that may influence the design of future clinical trials and the development of novel therapies. This study challenges the concept of apathy and ICD in PD as opposite ends of a spectrum.
Authors: Amy L Phu; Zheyu Xu; Vlasios Brakoulias; Neil Mahant; Victor S C Fung; Gregory De Moore; Andrew Martin; Vladan Starcevic; Martin Krause Journal: J Clin Neurosci Date: 2013-09-10 Impact factor: 1.961
Authors: Maddeson Riley; Megan Bakeberg; Michelle Byrnes; Alexa Jefferson; Soumya Ghosh; Rick Stell; Frank L Mastaglia; Dana Hince; Ryan S Anderton Journal: Parkinsons Dis Date: 2018-04-19
Authors: Francesca V Lopez; Lauren E Kenney; Adrianna Ratajska; Charles E Jacobson; Dawn Bowers Journal: Clin Neuropsychol Date: 2021-11-15 Impact factor: 4.373
Authors: Fernando Rodriguez-Sanchez; Carmen Rodriguez-Blazquez; Concha Bielza; Pedro Larrañaga; Daniel Weintraub; Pablo Martinez-Martin; Alexandra Rizos; Anette Schrag; K Ray Chaudhuri Journal: Sci Rep Date: 2021-12-08 Impact factor: 4.379
Authors: Frank H Hezemans; Noham Wolpe; Claire O'Callaghan; Rong Ye; Catarina Rua; P Simon Jones; Alexander G Murley; Negin Holland; Ralf Regenthal; Kamen A Tsvetanov; Roger A Barker; Caroline H Williams-Gray; Trevor W Robbins; Luca Passamonti; James B Rowe Journal: PLoS Comput Biol Date: 2022-05-09 Impact factor: 4.779